|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MUSCLE CELL BIOLOGY AND CELL MOTILITY
1Department of Physiology and 2Vascular Biology Center, University of Tennessee Health Science Center, Memphis, Tennessee
Submitted 19 May 2005 ; accepted in final form 4 November 2005
Recent data support the hypothesis that reactive oxygen species (ROS) play a central role in the initiation and progression of vascular diseases. An important vasoprotective function related to the regulation of ROS levels appears to be the antioxidant capacity of nitric oxide (NO). We previously reported that treatment with NO decreases phosphotyrosine levels of adapter protein p130cas by increasing protein tyrosine phosphatase-proline, glutamate, serine, and threonine sequence protein (PTP-PEST) activity, which leads to the suppression of agonist-induced H2O2 elevation and motility in cultured rat aortic smooth muscle cells (SMCs). The present study was performed to investigate the hypotheses that 1) IGF-I increases the activity of the small GTPase Rac1 as well as H2O2 levels and 2) NO suppresses IGF-I-induced H2O2 elevation by decreasing Rac1 activity via increased PTP-PEST activity and dephosphorylation of p130cas. We report that IGF-I induces phosphorylation of p130cas and activation of Rac1 and that NO attenuates these effects. The effects of NO are mimicked by the overexpression of PTP-PEST or dominant-negative (dn)-p130cas and antagonized by the expression of dn-PTP-PEST or p130cas. We conclude that IGF-I induces rat aortic SMC motility by increasing phosphotyrosine levels of p130cas and activating Rac1 and that NO decreases motility by activating PTP-PEST, inducing dephosphorylating p130cas, and decreasing Rac1 activity. Decreased Rac1 activity lowers intracellular H2O2 levels, thus attenuating cell motility.
hydrogen peroxide; protein tyrosine phosphatase-proline, glutamate, serine, and threonine sequence protein; p130cas
This article has been cited by other articles:
![]() |
D. D. Tang p130 Crk-Associated Substrate (CAS) in Vascular Smooth Muscle Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2009; 14(2): 89 - 98. [Abstract] [PDF] |
||||
![]() |
K. Ogden, J. M. Thompson, Z. Hickner, T. Huang, D. D. Tang, and S. W. Watts A new signaling paradigm for serotonin: use of Crk-associated substrate in arterial contraction Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2857 - H2863. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |